<SEC-DOCUMENT>0001193125-18-353929.txt : 20181220
<SEC-HEADER>0001193125-18-353929.hdr.sgml : 20181220
<ACCEPTANCE-DATETIME>20181220083056
ACCESSION NUMBER:		0001193125-18-353929
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20181220
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20181220
DATE AS OF CHANGE:		20181220

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		181244692

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d676533d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): December&nbsp;20, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17
CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this
chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Events </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;20, 2018, FibroGen, Inc. issued a press release in which it reported positive topline results from three pivotal Phase 3
studies of roxadustat, its potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> orally administered small molecule for the treatment of anemia in chronic kidney disease patients. These three
trials, ANDES, HIMALAYAS, and SIERRA, studied anemia in chronic kidney disease patients on dialysis, not on dialysis, and initiating dialysis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of such press release is furnished as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Financial Statements and Exhibits. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d676533dex991.htm">Press Release titled &#147;FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease&#148; dated December&nbsp;20,
 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"><B>FIBROGEN, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: December&nbsp;20, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Lowenstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Legal Officer</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d676533dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g676533g1219223256413.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen Announces Positive Topline Results from Three Global Phase 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Primary efficacy endpoints met in all three studies: </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">non-dialysis,</FONT> incident dialysis, and stable dialysis studies </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN FRANCISCO, December&nbsp;20, 2018 &#150; FibroGen, Inc. (NASDAQ:FGEN), a leading biopharmaceutical company discovering and developing a pipeline of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics, today announced that roxadustat, an inhibitor of hypoxia-inducible-factor (HIF) prolyl hydroxylase activity
<FONT STYLE="white-space:nowrap">(HIF-PHI),</FONT> met all primary efficacy endpoints in the three global pivotal Phase 3 trials conducted by FibroGen: ANDES in <FONT STYLE="white-space:nowrap">non-dialysis-dependent</FONT> (NDD) chronic kidney
disease (CKD) patients, HIMALAYAS in incident (newly initiated) dialysis patients, and SIERRAS in dialysis-dependent (DD) CKD patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Anemia in
CKD is a serious condition for which a significant number of patients are left without treatment options in many markets,&#148; said Thomas B. Neff, Chief Executive Officer, FibroGen. &#147;These Phase 3 results demonstrate the potential for
roxadustat to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> oral anemia therapeutic for CKD patients. This is the first well-controlled CKD anemia program that has shown improved efficacy in
incident and stable dialysis patients relative to ESA standard of care therapy.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the three studies had a
<FONT STYLE="white-space:nowrap">pre-specified</FONT> primary efficacy endpoint for meeting U.S. regulatory requirements and another <FONT STYLE="white-space:nowrap">pre-specified</FONT> primary efficacy endpoint for meeting EU regulatory
requirements, which also served as a secondary efficacy endpoint for the U.S. Both the U.S. and EU primary efficacy endpoints were met in all three studies. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Non-Dialysis CKD Patients Study (ANDES<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ANDES is a <FONT STYLE="white-space:nowrap">922-patient</FONT><B> </B>global Phase 3, randomized, double-blinded, placebo-controlled trial designed to evaluate
the efficacy and safety of roxadustat versus placebo for the treatment of anemia in patients with later-stage CKD (stages 3, 4 or 5) who are not dialysis-dependent.<SUP STYLE="font-size:85%; vertical-align:top">1</SUP> This study was conducted in
the U.S. and 14 other countries. Treatment duration was up to 4.5 years, with average duration of 1.7 years. Baseline hemoglobin (Hb) levels averaged 9.1 g/dL in both the roxadustat (N=616) and the placebo (N=306) arms. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>U.S. primary efficacy endpoint</U>: Roxadustat was superior to placebo in mean Hb change from baseline to
the average over Weeks <FONT STYLE="white-space:nowrap">28-52</FONT> (2.00 vs 0.16 g/dL, respectively, p&lt;0.0001). </P></TD></TR></TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>EU primary efficacy endpoint</U>: A higher proportion of roxadustat-treated patients (86.0%) achieved a Hb
response in the first 24 weeks (defined as achieving a Hb level of at least 11 g/dL and a Hb increase of at least 1 g/dL) as compared to placebo (6.6%), p=0.0007. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Furthermore, in a <FONT STYLE="white-space:nowrap">pre-specified</FONT> secondary efficacy analysis, roxadustat reduced the risk of rescue therapy by 81%
(hazard ratio (HR)=0.19) defined as the time to first use of blood transfusion, administration of an erythropoiesis stimulating agent (ESA) or IV iron in the first 52 weeks of treatment, p&lt;0.0001. In addition, roxadustat reduced the risk of blood
transfusion by 74% (HR = 0.26) in the time to first blood transfusion during the first 52 weeks of treatment, p&lt;0.0001. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incident Dialysis CKD
Patients Study (HIMALAYAS<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">HIMALAYAS is a <FONT STYLE="white-space:nowrap">1,043-patient</FONT>
global Phase 3 randomized, open-label, active-controlled trial to assess the efficacy and safety of roxadustat compared to epoetin alfa, an ESA, for the treatment of anemia in CKD patients who have newly initiated dialysis treatment for end stage
renal disease and have had minimal or no exposure to ESA prior to study participation.<SUP STYLE="font-size:85%; vertical-align:top">2</SUP> This study was conducted in the U.S. and 17 other countries.<B> </B>Treatment duration was up to 4.4 years,
with mean duration of 1.8 years. Mean baseline Hb was 8.43 g/dL in the roxadustat arm (N=522) and 8.46 g/dL in the epoetin alfa arm (N=521). </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>U.S. primary efficacy endpoint</U>: The mean Hb change from baseline to the average over Weeks <FONT
STYLE="white-space:nowrap">28-52</FONT> was 2.57 g/dL (roxadustat) vs. 2.36 g/dL (epoetin alfa), a least squares mean difference of 0.18 g/dL, with the 95% confidence interval (CI)&nbsp;of (0.08, 0.29). The
<FONT STYLE="white-space:nowrap">non-inferiority</FONT> criteria was met as the lower bound of the 95% CI was well above the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> margin of <FONT STYLE="white-space:nowrap">-0.75</FONT> g/dL, and
superiority over epoetin alfa was also achieved, p=0.0005. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>EU primary efficacy endpoint</U>: Roxadustat met the <FONT STYLE="white-space:nowrap">non-inferiority</FONT>
criteria compared to epoetin alfa: 88.2% of the roxadustat-treated patients achieved a Hb response in the first 24 weeks (defined as achieving a Hb level of at least 11 g/dL and a Hb increase of at least 1 g/dL) compared to an 84.5% responder rate
in the epoetin alfa arm; lower bound of the 95% CI <FONT STYLE="white-space:nowrap">(-0.9%,</FONT> 7.6%) of the treatment difference in responder rate is well above the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> margin of <FONT
STYLE="white-space:nowrap">-15%.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stable Dialysis CKD Patients Study
(SIERRAS<SUP STYLE="font-size:85%; vertical-align:top">3</SUP>) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SIERRAS is a <FONT STYLE="white-space:nowrap">741-patient</FONT> U.S. Phase 3,
randomized, open-label, active-controlled trial to assess the efficacy and safety of roxadustat compared to epoetin alfa for the treatment of anemia (in maintaining Hb level) in <FONT STYLE="white-space:nowrap">DD-CKD</FONT> patients who were
receiving stable doses of ESA prior to study participation.<SUP STYLE="font-size:85%; vertical-align:top">3</SUP> Treatment duration was up to 3.5 years, with a mean duration of 1.9 years. Mean baseline Hb levels were 10.3 g/dL in both roxadustat
and epoetin alfa arms. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>U.S. primary efficacy endpoint</U>: The mean Hb change from baseline to the average over Weeks <FONT
STYLE="white-space:nowrap">28-52</FONT> was 0.39 g/dL (roxadustat) vs <FONT STYLE="white-space:nowrap">-0.09</FONT> g/dL (epoetin alfa), a least squares mean treatment difference of 0.48 g/dL (95% CI 0.37, 0.59). Roxadustat met the <FONT
STYLE="white-space:nowrap">non-inferiority</FONT> criteria as the lower bound of 95% CI was well above the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> margin of <FONT STYLE="white-space:nowrap">-0.75</FONT> g/dL. Roxadustat also achieved
superiority, p&lt;0.0001.<U> </U> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>EU primary efficacy endpoint</U>: The mean Hb change from baseline to the average over Weeks <FONT
STYLE="white-space:nowrap">28-36</FONT> was 0.54 g/dL (roxadustat) vs <FONT STYLE="white-space:nowrap">-0.02</FONT> g/dL (epoetin alfa), a least squares mean treatment difference of 0.53 g/dL with a 95% CI (0.39, 0.67). Roxadustat met the <FONT
STYLE="white-space:nowrap">non-inferiority</FONT> criteria as the lower bound of the 95% CI was well above the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> margin of <FONT STYLE="white-space:nowrap">-0.75</FONT> g/dL. Roxadustat also
achieved superiority over epoetin alfa, p&lt;0.0001. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, in the <FONT STYLE="white-space:nowrap">pre-specified</FONT>
secondary efficacy analysis, roxadustat-treated patients had a 33% reduction in the risk of blood transfusion compared to epoetin alfa (HR=0.67) in the time to first blood transfusion during treatment, p=0.0337. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 2 of 5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preliminary safety analyses of each of these three individual studies show an overall safety profile
consistent with the results observed in prior roxadustat studies. The adverse events reported are consistent with those expected in these study populations with similar background diseases. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These three Phase 3 studies sponsored and conducted by FibroGen are part of FibroGen&#146;s <FONT STYLE="white-space:nowrap">co-development</FONT>
collaboration with AstraZeneca AB and with Astellas Pharma Inc. These studies are part of the roxadustat global Phases 3 program, which consists of multiple global studies in more than 50 countries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Results of the pooled safety analyses, including the major adverse cardiovascular events (MACE) for both <FONT STYLE="white-space:nowrap">NDD-CKD</FONT> and <FONT
STYLE="white-space:nowrap">DD-CKD</FONT> in the global Phase 3 program is anticipated prior to U.S. NDA submission in the first half of 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We
are excited to have achieved superiority in efficacy not only against placebo but also over active comparator in our studies,&#148; said K. Peony Yu, MD, Chief Medical Officer, FibroGen. &#147;These results support roxadustat&#146;s potential to
bring clinical benefit over current standard of care, such as reducing blood transfusion risk in patients on dialysis and those not on dialysis, and to improve patient access to anemia therapy with a new convenient oral therapeutic.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">AstraZeneca also announced positive topline results today from its roxadustat phase 3 trials; OLYMPUS<SUP STYLE="font-size:85%; vertical-align:top">4</SUP> in
<FONT STYLE="white-space:nowrap">NDD-CKD</FONT> and ROCKIES<SUP STYLE="font-size:85%; vertical-align:top">5</SUP> in <FONT STYLE="white-space:nowrap">DD-CKD.</FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Anemia Associated with CKD </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anemia can be a serious
medical condition in which patients have insufficient red blood cells and low levels of Hb, a protein in red blood cells that carries oxygen to cells throughout the body.<SUP STYLE="font-size:85%; vertical-align:top">6,7</SUP> Anemia in CKD is
associated with increased risk of hospitalization, cardiovascular complications and death,<SUP STYLE="font-size:85%; vertical-align:top">8</SUP> also frequently causing significant fatigue, cognitive dysfunction and reduced quality of life.<SUP
STYLE="font-size:85%; vertical-align:top">9</SUP> Severe anemia is common in patients with CKD, cancer, myelodysplastic syndromes (MDS), inflammatory diseases, and other serious illnesses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anemia is particularly prevalent in patients with CKD. The prevalence of CKD in the adult population is estimated at
<FONT STYLE="white-space:nowrap">10-12%</FONT> globally,<SUP STYLE="font-size:85%; vertical-align:top">10</SUP> and is generally a progressive disease characterized by gradual loss of kidney function that may eventually lead to kidney failure, or
end stage renal disease, requiring dialysis or kidney transplant to survive. Blood transfusion is used for treating life-threatening severe anemia. However, blood transfusions reduce the patient&#146;s opportunity for kidney transplant, increase
risk of infections and the risk of complications such as heart failure and allergic reactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">According to the United States Renal Data System (USRDS),
over 14% of the U.S. adult population is affected by CKD, and a majority of dialysis-eligible CKD patients are currently on dialysis. It is estimated that approximately 507,000 patients are receiving dialysis in the U.S. as of 2016.<SUP
STYLE="font-size:85%; vertical-align:top">11</SUP> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Roxadustat </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat <FONT STYLE="white-space:nowrap">(FG-4592),</FONT> discovered by FibroGen, is a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class,</FONT></FONT> orally administered small molecule currently approved in China for the treatment of anemia in CKD patients on dialysis. Roxadustat is a <FONT
STYLE="white-space:nowrap">HIF-PHI</FONT> that promotes erythropoiesis through increasing endogenous production of erythropoietin, improving iron regulation, and overcoming the negative impact of inflammation on hemoglobin syntheses and red blood
cell production by downregulating hepcidin. Administration of roxadustat has been shown to induce coordinated erythropoiesis, increasing red blood cell count while maintaining plasma erythropoietin levels within or near normal physiologic range in
multiple subpopulations of CKD patients, including in the presence of inflammation and without a need for supplemental intravenous iron.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 3 of 5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen and collaboration partners are pursuing four approval pathways in major jurisdictions to prepare
for commercialization worldwide: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the treatment
of anemia in territories including Japan, Europe, the Commonwealth of Independent States, the Middle East, and South Africa. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">AstraZeneca and FibroGen are collaborating on the development and commercialization of roxadustat for the
treatment of anemia in the U.S., China, and other markets in the Americas and in Australia/New Zealand as well as Southeast Asia. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen and its partners have completed 35 Phase 1 and Phase 2 studies. The Phase 2 clinical studies have consistently demonstrated anemia correction and
maintenance of hemoglobin levels in multiple subpopulations across a wide spectrum of CKD patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Globally, the Phase 3 program encompasses a total of
15 Phase&nbsp;3 studies of roxadustat in both <FONT STYLE="white-space:nowrap">non-dialysis-dependent</FONT> and dialysis-dependent CKD patients to support independent regulatory approvals in the U.S., Europe, Japan, and China. To date, positive
topline results have been announced for 12 of the Phase 3 studies, with two supporting the China NDA for treatment of anemia in CKD patients on dialysis and not on dialysis, four supporting the Japan NDA for treatment of anemia in CKD patients on
dialysis, and six supporting the U.S./EU submissions including today&#146;s announcement of 3 studies by FibroGen. Roxadustat was approved by China National Medical Products Administration (NMPA) in December 2018, for treatment of anemia in CKD
patients on dialysis. The Japan NDA submitted by Astellas is under review by the Japan Pharmaceuticals and Medical Devices Agency (PMDA). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat is
currently in Phase 3 clinical development for the treatment of anemia associated with MDS in the U.S. and in Phase 2/3 development for MDS in China. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., headquartered in San
Francisco, California, with subsidiary offices in Beijing and Shanghai, People&#146;s Republic of China, is a leading biopharmaceutical company discovering and developing a pipeline of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics.&nbsp;The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth factor (CTGF) biology, and
clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#146;s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity,
completing worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application (NDA) now approved by the National Medical Products Administration (NMPA) in China. Our partner Astellas
submitted a NDA for the treatment of anemia in CKD patients on dialysis in Japan in September 2018, which is currently under review by the Pharmaceuticals and Medical Devices Agency (PMDA). Roxadustat is in Phase 3 clinical development in the U.S.
and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS).&nbsp;Pamrevlumab, an anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic
pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information, please visit <U>www.fibrogen.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains
forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the company&#146;s product candidates pamrevlumab and roxadustat, the potential safety and efficacy profile of our
product candidates, and our clinical, regulatory plans, and those of our partners. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts
and typically are identified by use of terms such as &#147;may,&#148; &#147;will&#148;, &#147;should,&#148; &#147;on track,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148;
&#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;continue&#148; and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these
forward-looking statements due to risks and uncertainties related to the continued progress </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 4 of 5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended September&nbsp;30, 2018 filed with the Securities and
Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to
update any forward-looking statement in this press release, except as required by law.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>References </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Data on File. A Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of
Roxadustat <FONT STYLE="white-space:nowrap">(FG-4592)</FONT> for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis. December 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Data on File. A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of the Efficacy and
Safety of <FONT STYLE="white-space:nowrap">FG-4592</FONT> in the Treatment of Anemia in Incident-dialysis Patients. December 2018 </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Data on File. A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of
Roxadustat <FONT STYLE="white-space:nowrap">(FG-4592)</FONT> in the Maintenance Treatment of Anemia in Subjects with End Stage Renal Disease (ESRD) on Stable Dialysis. December 2018. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clinicaltrials.gov. Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients with Chronic Kidney
Disease (CKD), Not on Dialysis. [Online]. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02174627. Last accessed: December 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Clinicaltrials.gov. Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients with Chronic Kidney
Disease, on Dialysis. [Online]. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02174731. Last accessed: December 2018. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">National Kidney Foundation. &#147;Managing Anemia When You Have Kidney Disease or Kidney Failure.&#148; 2014.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">National Institute of Diabetes and Digestive and Kidney Diseases. &#147;Anemia in Chronic Kidney Disease.&#148;
2014. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Babitt JL, Lin HY. Mechanisms of Anemia in CKD. J Am Soc Nephrol (2012); 23:1631-1634. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.
Am J Kidney Dis. 2006 <FONT STYLE="white-space:nowrap">May;47(5):S1-S132</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Mills et al. Kidney International 2015; 88: 950&#150;957 </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">United States Renal Data System (USRDS). Annual Data Report 2017. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 (415) <FONT STYLE="white-space:nowrap">978-1433</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>kbergman@fibrogen.com </U></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Page 5 of 5 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g676533g1219223256413.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g676533g1219223256413.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !0 2\# 2(  A$! Q$!_\0
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MB2ABC!MK%3CL1U%(H?1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)'N:*/YB#C)Z?UJWI22)I=OYP F9-\@ _B;D_J:P9Q;+I5O8V]HRK<7'E%E
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M8T"H%Z  <5Y=\;+:W^PZ3=;0+GSFBSW*;<_H0/SHC)2?*T#32O<VOBGJHB\
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M11VT4,TDD8VF0Y< \$^N/6I:**"@HHHH **** "BBB@ HHHH **** "BBB@
BHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
